NURPF Company Profile and Key Details

PNK : NURPF

Neuren Pharmaceuticals

$14.00

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Neuren Pharmaceuticals Limited (NURPF) stock remained unchanged at $8.53 a share on OTC. The stock opened at $12.02, fluctuating between $8.53 to $12.02 during the session.

Stock Snapshot

8.525

Prev. Close

1.08B

Market Cap

8.525

Day Low

50.15

P/E Ratio

0.17

EPS (TTM)

2.18

Cash Flow per Share

12.02

Open

126.64M

Number of Shares

12.02

Day High

86.35%

Free Float in %

1.61

Book Value

100

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 23, 2026	8.53	8.53	8.53	8.53	2.01K
Feb 10, 2026	9.86	9.86	9.86	9.86	100
Jan 29, 2026	12.02	12.02	12.02	12.02	200
Jan 28, 2026	12.02	12.02	12.02	12.02	100
Jan 27, 2026	12.20	12.20	12.20	12.20	100
Jan 15, 2026	12.91	12.91	12.91	12.91	150
Jan 14, 2026	15.15	15.15	15.15	15.15	1
Dec 31, 2025	12.91	12.91	12.91	12.91	1K
Dec 03, 2025	10.97	12.45	10.97	12.45	100
Dec 01, 2025	11.01	11.01	11.01	11.01	2.9K
Nov 10, 2025	12.25	12.25	12.25	12.25	250
Nov 07, 2025	12.91	12.91	12.91	12.91	190
Nov 04, 2025	11.73	11.73	11.73	11.73	4.25K
Oct 31, 2025	13.90	13.90	13.90	13.90	70
Oct 27, 2025	13.35	13.35	13.35	13.35	5K
Oct 16, 2025	13.19	13.19	11.82	11.82	2.1K
Oct 02, 2025	14.80	14.80	14.80	14.80	400
Oct 01, 2025	13.09	13.09	13.09	13.09	269
Sep 30, 2025	13.00	13.00	13.00	13.00	275
Sep 29, 2025	13.40	13.40	13.40	13.40	50

Contact Details

Camberwell, VIC 3124

Australia

https://www.neurenpharma.com 613 909 20480

About Company

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Stock Peers

ODTC

Odonate Therapeutics, Inc.$2,849.50 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 NONOF

Novo Nordisk A/S$144.95 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 FNCH

-0.05-0.38%

Finch Therapeutics Group, Inc.$13.20 TLPPF

Telix Pharmaceuticals Limited$11.00

Company Overview

The stock is currently mid-range between its 52-week high and low $6.60 and $14.80. With a market capitalization of about $1.08 billion, Neuren Pharmaceuticals Limited is classified as a small-cap and shows higher-than-market volatility (beta ~1.61). Key stats such as the average daily volume over the past year has been around 145.00 shares, volume is running light vs its 52-week average. Headquartered in Camberwell, VIC, Neuren Pharmaceuticals Limited operates in the Healthcare sector and the Biotechnology industry. Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders.

Technical Performance

Average 10-day trading volume of 2.01 thousand shares is significantly above the 3-month average of 417.89, indicating heightened recent market interest.

Valuation Metrics

Neuren Pharmaceuticals Limited trades at a P/E ratio of 70.63, slightly above the S&P 500 average, with a price-to-sales ratio of 33.26 and a price-to-book ratio of 6.35 trading at moderately above to book value. The P/FCF stands at 17.14, also above market averages.

Dividend & Fair Value

Neuren Pharmaceuticals Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.77. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Neuren Pharmaceuticals Limited earnings surprise history is a mixed track record. The quarter that ended August 26, 2025, missed forecasts by 2.14%. The prior quarter beat by -0.94%. Over the last six quarters, Apple has recorded several small beats. These include -15.1% in February 28, 2024.

Financial & Profitability Overview

Over the trailing twelve months, Neuren Pharmaceuticals generated $231.93M in revenue, or $1.77 per share. Gross margin was 88.47%, operating margin 85.90%, and net profit margin 67.73%. Returns are exceptional, with ROA at 63.35% and ROE at 76.55%.
On valuation metrics, Neuren Pharmaceuticals trades at a P/E of 70.63, P/S of 33.26 and P/B of 6.35. The current ratio is 76.60 and quick ratio is 76.60. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 91.09 days.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Neuren Pharmaceuticals posted revenue of $231.93M, down slightly from $14.55M in the prior quarter. Gross profit was $205.17M (margin 88.47%). Operating income was $199.23M (margin 85.9%). Net income was$157.08M (EPS $1.24).
The company ended the quarter with $228.54M in cash and short-term investments, a total debt of $0.00, and net debt of - $17.09M. Total assets were $247.97M, with equity of $205.21M. Financials further reflected stability, with operating cash flow of $184.93M, free cash flow of $184.89M, and capital expenditures of - $40.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Neuren Pharmaceuticals Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows Neuren Pharmaceuticals Limited trading at a premium to the broader market with a P/E of 70.63.

Frequently Asked Questions

What is the current Neuren Pharmaceuticals Limited (NURPF) stock price?

Neuren Pharmaceuticals Limited (OTC: NURPF) stock price is $8.53 in the last trading session. During the trading session, NURPF stock reached the peak price of $12.02 while $8.53 was the lowest point it dropped to. The percentage change in NURPF stock occurred in the recent session was 0% while the dollar amount for the price change in NURPF stock was $0.00.

NURPF's industry and sector of operation?

The OTC listed NURPF is part of Biotechnology industry that operates in the broader Healthcare sector. Neuren Pharmaceuticals Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of NURPF?

Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.
Chief Executive Officer, MD & Executive Director
Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons)
Chief Executive Officer, MD & Director
Mr. Lawrence Glass
Chief Science Officer
Ms. Lauren Frazer C.A.
Chief Financial Officer & Company Sec.
Dr. Liza A. Squires M.D.
Chief Medical Officer
Mr. Gerry Zhao
Vice President of Corporation Devel.
Mr. Lawrence Glass BA (Biology)
Chief Science Officer

How NURPF did perform over past 52-week?

NURPF's closing price is 126.9% higher than its 52-week low of $6.60 where as its distance from 52-week high of $14.80 is -18.63%.

How many employees does NURPF have?

Number of NURPF employees currently stands at 0.

Link for NURPF official website?

Official Website of NURPF is: https://www.neurenpharma.com

How do I contact NURPF?

NURPF could be contacted at phone 613 909 20480 and can also be accessed through its website. NURPF operates from 697 Burke Road, Camberwell, VIC 3124, Australia.

How many shares of NURPF are traded daily?

NURPF stock volume for the day was 100 shares. The average number of NURPF shares traded daily for last 3 months was 145.

What is the market cap of NURPF currently?

The market value of NURPF currently stands at $1.08B with its latest stock price at $8.53 and 126.64M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	0
Beta	1.74
Sales or Revenue	$231.93M
5Y Sales Change%	11.921%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

NURPF Company Profile and Key Details

Neuren Pharmaceuticals

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Key Takeaways

Price Forecast & Outlook

Valuation Metrics